Strata Critical MedicalSRTA
Recorded

Strata Critical Medical 2026 UBS Global Healthcare Conference

Review the key takeaways and the transcript of this earnings call.

Period 2026Duration35 minParticipants4

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Patrick WoodHead of US MedTech Research

Picks the songs. That's the key. Who picks the playlist? Welcome, everyone. It's Patrick Wood on the UBS MedTech team. It's a delight to have Melissa, Will, and Matt here today, who collectively are the dream team at Strata. Thanks very much for coming, guys. Really appreciate the time. I think, maybe to level set people, probably 18 months, two years ago, people kind of knew you as Blade. You're in a different spot. Today, you're in a very different form of business, fast growth area. Maybe just to make sure everyone's on the same page, walk people through that journey to what you are today. I'll throw it open to any of you. Fight over who has to answer.

Will HeyburnCo-CEO and CFO

For several years, the fastest growing part of our business was our healthcare segment, focused on transplant, where, for folks who aren't familiar, there is a huge problem in America, which is there are not enough donor organs, and there is extremely high demand for people who, if they don't get these donor organs, they're unfortunately not going to be able to survive. The way that we've been able to help solve this problem with the people that we partner with at transplant centers and organ procurement organizations and with medical device companies is to do what we can to increase the supply of donor organs that can be utilized.

Will HeyburnCo-CEO and CFO

It's led to significant growth in the number of transplants that happen in America, and it's also led to pretty dramatic growth, averaging about 15% per year, in the number of donation after circulatory death transplants that happen in the United States. It's a whole new category of organ donor that's been enabled by technology, by new regulation, and Strata has tried to put all the pieces together in a single integrated offering to partner with transplant centers, which are the hospitals that have the patient that's going to receive the transplant, partner with OPOs, which are the groups that help identify donors, to come up with the most efficient, cost-effective way to be able to successfully recover organs from those donors and get them very quickly, because you have very limited time, to the recipients for whom it will be a life-saving procedure.

Will HeyburnCo-CEO and CFO

As we saw the opportunity, the need, we decided about a year ago, to your point, to divest the passenger part of our business, focus entirely on this, and then add clinical capabilities to create that full end-to-end offering. So now, not only are we providing the logistics, we're providing surgeons that can recover organs. We're providing perfusion, so we provide normothermic regional perfusion, where machines are able to repair the damage that's done in the dying process to those organs. It's a very cost-effective way to enable you to use an organ from a donor whose heart has stopped. Then we also are able to partner with device companies to either transport or operate other kinds of machines that can do very similar things.

Will HeyburnCo-CEO and CFO

We think we have created really what we call an open source infrastructure layer for the transplant community, and importantly, we build that clinical part of our business on the very sturdy foundation of a company that provides services in terms of perfusion for regular way cardiac surgeries to hundreds of hospitals across the U.S. It happens to be the same kind of people, perfusionists, and the same equipment that you use in those situations that we can also use in our transplant scenarios. We get some economies of scale, and we're growing incredibly quickly, both organically and through acquisition, because all this change in transplant, which has been for the better, which has resulted in a lot of growth, has meant that some of the old ways of doing things, which were very regionalized, are no longer the standard practice.

Will HeyburnCo-CEO and CFO

That has meant that a lot of the smaller providers of services like ours, because they don't have the national scale, they're no longer able to meet all their customers' needs. That's resulted in us taking some share. It's also resulted in us partnering with a lot of those companies through acquisition, bringing them into our platform, bringing great people, great clinicians into the Strata business, and then making everything run more efficiently, both for those individuals that now can spend more time in operating rooms and less time on airplanes, and for our customers. We're thrilled with the transition we've made. We're thrilled with the opportunity we have to help, in our way, solve this really important life-saving problem that everyone's facing in America. We have so many different ways to achieve that objective, both organically and through acquisition.

Will HeyburnCo-CEO and CFO

Couldn't be more excited about the decisions that we've made strategically and the opportunities that we have ahead.

Patrick WoodHead of US MedTech Research

Definitely want to dig into all of those. Melissa, you had a background in aviation before. Obviously, healthcare has its own distinctions versus passenger, with some very obvious differences between the two. Were there things that surprised you on the healthcare aviation side that you weren't expecting around challenges or unique ways of having to run that business versus the other side?

Melissa TomkielCo-CEO and General Counsel

Well, the biggest difference is the 24-hour nature of the healthcare business. It takes the right operators, the right mentality amongst pilots and mechanics to really staff up an organization that's accessible 24/7. The best thing going for us here is that we're mission-driven, right? Everyone knows that all of those flights result in saving lives. That's probably the biggest distinction. The other one being, with organ donation, with DCDs, unfortunately about a quarter of the time, it's what we call a dry run, meaning the donor didn't decease quickly enough, the organs are unusable, and the recovery surgeon goes home empty-handed. That doesn't happen in normal aviation, but what it allows for, what it presents itself for is the ability to provide the most cost-efficient way to handle those situations for our transplant center customers.

Melissa TomkielCo-CEO and General Counsel

The way to do that is to have the national scale with our 20 or so aviation hubs that are strategically around the country, so that when we have a plane in place where a donor is, if it's a dry run, we haven't fired up an engine. It's minimal cost to our customer, as opposed to having to fly out from the transplant center, fly a team in, fly back empty-handed. Now you've just burned the transplant center's surgeon's time. You've burned a lot of their money because they're paying for a private jet to fly somewhere and back with no organ. Building the national infrastructure with aviation hubs coupled with local surgeons who are available to, we call it self-report, to drive or fly commercially to the donor OR is the key differentiator here.

Melissa TomkielCo-CEO and General Counsel

This is where we are set apart from the very good, but the very local operators that we are either competing with or working with, or some of whom have been acquisition targets. That's really the biggest difference in how you think about optimizing for cost efficiency and time efficiency, because every minute matters when you're transporting a heart that's outside of a body. The more assets you have in the more strategic locations is going to give you that advantage.

Patrick WoodHead of US MedTech Research

To that network effect, and both of you in your answers talked about M&A, naturally. Matt and all of you, how do you think about the M&A capacity here, the ability to get that network effect, to get larger? How do you think about capital allocation from an M&A perspective?

Will HeyburnCo-CEO and CFO

Want to take that, Matt?

Mathew SchneiderCFO of Clinical Services and VP of Finance and Investor Relations

There's a significant opportunity to strengthen exactly what Melissa just said. We have this integrated platform, local delivery network that we're building, and entering additional geographic areas across the country would strengthen that because the more time we can deliver our services when we're closer to the donor hospital, the more cost efficiencies we could deliver to the customer. We're building out the platform to try to be in more areas to diversify our customer exposure and to be able to deliver that operational cost savings more of the time. That's across both our NRP perfusion, our surgical recovery network and services, our CT or cardiothoracic perfusion services, and really across logistics. The more places we are across the country closer to the customer, the better we're able to deliver that savings to the customer.

Mathew SchneiderCFO of Clinical Services and VP of Finance and Investor Relations

That's what we're really focused on, strengthening the value proposition to the customer. There's also just the financial rationale behind it of how we're going to market, the acquisitions we're doing, the multiples that we're acquiring the companies at, and we're really excited about deploying capital going forward from here.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.

View the full transcript with Pro

Other earnings calls that day

View calls from this day